Market Overview

Global Colorectal Cancer (CRC) Drugs/ Therapeutic Market 2016-2022: Bristol-Myer Squibb and Merck are Anticipated to be Market Leaders by 2022

Share:

Global Colorectal Cancer (CRC) Drugs/ Therapeutic Market 2016-2022: Bristol-Myer Squibb and Merck are Anticipated to be Market Leaders by 2022

PR Newswire

DUBLIN, Aug. 23, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, exhibiting a CAGR of 3.3% during the forecast period. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Further key findings from the report suggest:

  • Immunotherapy dominated the market based on drug class in 2016, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2016 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2016. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.

Key Topics Covered:

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Stages
3.1.2 Symptoms
3.1.3 Risk Factors
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Colorectal Cancer Drugs Market Overview
4.1 Introduction and Market Overview
4.1.1 Segmentation, by Drug Class
4.1.1.1 Chemotherapy
4.1.1.1.1 Antimetabolites
4.1.1.1.2 Alkylating agents
4.1.1.2 Immunotherapy
4.1.1.2.1 Biologic Response Modifiers
4.1.1.2.2 Colony-Stimulating Factors
4.1.1.2.3 Tumor Vaccines
4.1.1.2.4 Monoclonal Antibodies
4.1.2 Segmentation, by Region
4.1.2.1 U.S.
4.1.2.2 U.K.
4.1.2.3 Germany
4.1.2.4 Spain
4.1.2.5 Italy
4.1.2.6 France
4.1.2.7 Japan
4.1.3 Market size and forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (YTD 2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 SWOT Analysis

Chapter 5 Colorectal Cancer Drugs Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Drugs in development
5.1.2 Key R&D trends
5.1.2.1 Molecular targeted therapy
5.1.2.2 Immunotherapy
5.1.2.3 Biosimilars
5.2 Promising Drugs
5.2.1 Late-stage pipeline
5.2.2 Profile of disruptive drugs
5.2.2.1 Tecentriq
5.2.2.2 Binimetinib+Encorafenib+Cetuximab
5.2.2.3 MK-3475-177
5.2.2.4 Napabucasin

Chapter 6 Company Profiles

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck
  • Roche
  • Sanofi

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/kwdjm8/global_colorectal?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/global-colorectal-cancer-crc-drugs-therapeutic-market-2016-2022-bristol-myer-squibb-and-merck-are-anticipated-to-be-market-leaders-by-2022-300701768.html

SOURCE Research and Markets

View Comments and Join the Discussion!